FDA boxed warnings: How to prescribe drugs safely

American Family Physician

Volumn 81, Issue 3, 2010, Pages 298-303

  O'Connor, Nina R ^a  

^a Chestnut Hill Family Practice Residency Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMIODARONE; ATENOLOL; ATOMOXETINE; BUMETANIDE; CERIVASTATIN; CISAPRIDE; CLOZAPINE; DULOXETINE; ENALAPRIL; ENALAPRIL MALEATE; ESTRADIOL; FENTANYL; FERROUS SULFATE; FLUOXETINE; FUROSEMIDE; GENTAMICIN; HYDROMORPHONE; IBUPROFEN; IRBESARTAN; LISINOPRIL; METOPROLOL; METRONIDAZOLE; NAPROXEN; PEMOLINE; PEMOLINE MAGNESIUM; PERGOLIDE; PERGOLIDE MESILATE; PIMECROLIMUS; PIOGLITAZONE; RALOXIFENE; ROFECOXIB; ROSIGLITAZONE; SALMETEROL XINAFOATE; TACROLIMUS; TEGASEROD; TELITHROMYCIN; TOBRAMYCIN; TROGLITAZONE; UNINDEXED DRUG; VALDECOXIB; VALSARTAN; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; PHOSPHATE; PRESCRIPTION DRUG; QUINOLONE DERIVATIVE; SALBUTAMOL; SALMETEROL; SODIUM DIHYDROGEN PHOSPHATE;

ADVERSE OUTCOME; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CONSTIPATION; CONSUMER; DRUG APPROVAL; DRUG INFORMATION; DRUG LABELING; DRUG MANUFACTURE; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HEALTH CARE PERSONNEL; HUMAN; HYPERACTIVITY; HYPERLIPIDEMIA; INFLAMMATION; INTESTINE PREPARATION; IRON THERAPY; IRRITABLE COLON; LIVER TOXICITY; MEDICATION ERROR; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PARKINSON DISEASE; PATIENT SELECTION; PHARMACIST; PRACTICE GUIDELINE; PRESCRIPTION; QT PROLONGATION; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; VALVULAR HEART DISEASE; DRUG TOXICITY; REVIEW; UNITED STATES;

ALBUTEROL; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; DRUG APPROVAL; DRUG LABELING; DRUG TOXICITY; FLUOROQUINOLONES; HUMANS; PHOSPHATES; PRESCRIPTION DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77449115991     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Murphy S, Roberts R. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol. 2006;117(1):34-39.
2. Guidance. Drug safety information - FDA's communication to the public. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm072281.pdf. Accessed November 24, 2009.
3. U.S. Food and Drug Administration. Adverse Event Reporting System (AERS) statistics. http://www.fda.gov/drugs/guidancecompliance regulatoryinformation/ surveillance/adversedrugeffects/ucm070093. htm. Accessed November 23, 2009.
4. Tufts Center for the Study of Drug Development. Drug safety withdrawals in the U.S. not linked to speed of FDA approval. Tufts CSDD Impact Report. 2005;7(5):1-4. http://csdd.tufts.edu/InfoServices/Impact ReportsArchive.asp?subsection=2005 (subscription required). Accessed October 14, 2009.
5. U.S. Food and Drug Administration. Index to drug-specific information. http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm. Accessed October 14, 2009.
6. Guidance for Industry. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products - content and format. http://www.fda. gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm075096.pdf. Accessed November 24, 2009.
7. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215-2220.
8. Proliferation of drugs with black-box warnings and required MedGuides. Pharmacist's Letter/Prescriber's Letter. 2006;22(220331). http://www. prescribersletter.com (subscription required). Accessed December 23, 2009.
9. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281(18):1728-1734.
10. Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J. 1998;53(3):403-411.
11. Brunelli SM, Feldman HI, Latif SM, Gupta M, Weiner MG, Lewis JD. A comparison of sodium phosphosoda purgative to polyethylene glycol bowel preparations prior to colonoscopy. Fam Med. 2009;41(1):39-45.
12. Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol. 2005;16(11):3389-3396.
13. Khurana A, McLean L, Atkinson S, Foulks CJ. The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy. Arch Intern Med. 2008;168(6):593-597.
14. Singal AK, Rosman AS, Post JB, Bauman WA, Spungen AM, Korsten MA. The renal safety of bowel preparations for colonoscopy: a comparative study of oral sodium phosphate solution and polyethylene glycol. Aliment Pharmacol Ther. 2008;27(1):41-47.
15. Russmann S, Lamerato L, Marfatia A, et al. Risk of impaired renal function after colonoscopy: a cohort study in patients receiving either oral sodium phosphate or polyethylene glycol. Am J Gastroenterol. 2007;102(12):2655-2663.
16. van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum. 2001;45(3):235-239.
17. Corrao G, Zambon A, Bertù L, et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf. 2006;29(10):889-896.
18. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404-1410.
19. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, for the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol [published correction appears in Chest. 2006;129(5):1393]. Chest. 2006;129(1):15-26.
20. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144(12):904-912.
21. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med. 2008;178(10):1009-1016.
22. Ni CM, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst Rev. 2005;(2): CD005307.
23. Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev. 2005;(4): CD005535.
24. Walters EH, Walters JA, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma. Cochrane Database Syst Rev. 2002;(4):CD003901.
25. Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med. 2006;166(3):338-344.
26. Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 2001;323(7309):378-381.
27. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA. 2002;287(17):2273-2275.
28. Shaughnessy AF. STEPS drug updates [editorial]. Am Fam Physician. 2003;68(12):2213.
29. Drug Effectiveness Review Project (DERP). http://www.ohsu.edu/ drugeffectiveness. Accessed October 14, 2009.